MANAGEMENT Rachel Blasbalg » Senior Director, Human Resources James Dentzer » President & CEO Christine Guertin » Vice President, Regulatory Affairs & Quality Assurance Robert Martell, M.D., Ph.D. » Head of Research & Development Mark Noel » Vice President, Technology Management and Intellectual Property Reinhard von Roemeling, M.D. » Senior Vice President, Clinical Development Raul Soikes » Vice President, Portfolio Management Nancy Soohoo » General Counsel Bill Steinkrauss » Chief Financial Officer © Curis, Inc. 2021 - All Rights Reserved Terms of Use Privacy Policy , in accordance with our privacy policies. I Understand ABOUT COLLABORATIONS PATIENTS PIPELINE INVESTORS CAREERS CONTACT

PRESS RELEASES Investor Alerts YEAR All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 KEYWORDS Go Advanced Search Nov 9, 2021 Curis Reports Third Quarter 2021 Financial Results and Business Update Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter... Nov 9, 2021 Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a poster presentation with new preclinical... Nov 8, 2021 Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes - Initial data expected in 2022 - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the... Nov 2, 2021 Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third... Nov 2, 2021 Curis to Present at Upcoming Investor Conferences Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that Curis management will participate in... Show 5 per page «123456789…94» © Curis, Inc. 2019 - All Rights Reserved Terms of UsePrivacy Policy , in accordance with our privacy policies. I Understand